What question did this study set out to answer?

The study aims to evaluate the health-related quality of life (HRQoL) in patients receiving nivolumab combined with gemcitabine-cisplatin compared to gemcitabine-cisplatin alone.

March 1, 2026Open Access

Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial

Key Points

The study aims to evaluate the health-related quality of life (HRQoL) in patients receiving nivolumab combined with gemcitabine-cisplatin compared to gemcitabine-cisplatin alone.
Phase III trial design
Comparison of nivolumab plus gemcitabine-cisplatin to gemcitabine-cisplatin alone
Assessment of HRQoL over 16 weeks of therapy
Nivolumab did not worsen HRQoL compared to gemcitabine-cisplatin alone
Findings support the standard use of nivolumab plus gemcitabine-cisplatin in cisplatin-eligible patients
Results maintained consistency over the first 16 weeks of treatment.

Abstract

Adding nivolumab to gemcitabine-cisplatin did not worsen HRQoL compared with gemcitabine-cisplatin alone in the first 16 weeks of therapy. These findings support nivolumab plus gemcitabine-cisplatin as standard first-line therapy for cisplatin-eligible patients with unresectable or metastatic UC.

Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial

Key Points

Abstract

Cite This Study